Literature DB >> 15936796

Cell-type-dependent activation of the cellular EF-1alpha promoter by the varicella-zoster virus IE63 protein.

Tricia Zuranski1, Hesham Nawar, Donna Czechowski, Jennifer M Lynch, Ann Arvin, John Hay, William T Ruyechan.   

Abstract

The varicella-zoster virus (VZV) IE63 protein is abundantly expressed during productive viral infection and is one of six gene products that appear to be expressed during latency. We have found that the IE63 protein can activate expression from the cellular EF-1alpha promoter in the absence of other viral proteins. The VZV IE62 protein, in contrast, was not found to transactivate this promoter. These data indicate that IE63 can function independently of the IE62 protein to positively influence the cellular transcription apparatus. We show that IE63 activation of the EF-1alpha promoter is cell type dependent and have examined the effects of point mutations important for IE63 phosphorylation and virus viability on this activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936796     DOI: 10.1016/j.virol.2005.05.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein.

Authors:  Mohamed I Khalil; Ann Arvin; Jeremy Jones; William T Ruyechan
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication.

Authors:  Mohamed I Khalil; Xibing Che; Phillip Sung; Marvin H Sommer; John Hay; Ann M Arvin
Journal:  Virology       Date:  2016-02-23       Impact factor: 3.616

3.  Varicella zoster virus infection of human fetal lung cells alters mitochondrial morphology.

Authors:  Amy C Keller; Hussain Badani; P Mason McClatchey; Nicholas L Baird; Jacqueline L Bowlin; Ron Bouchard; Guey-Chuen Perng; Jane E B Reusch; Benedikt B Kaufer; Don Gilden; Aamir Shahzad; Peter G E Kennedy; Randall J Cohrs
Journal:  J Neurovirol       Date:  2016-05-31       Impact factor: 2.643

Review 4.  Molecular mechanisms of varicella zoster virus pathogenesis.

Authors:  Leigh Zerboni; Nandini Sen; Stefan L Oliver; Ann M Arvin
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

5.  Two alphaherpesvirus latency-associated gene products influence calcitonin gene-related peptide levels in rat trigeminal neurons.

Authors:  Mohamed A Hamza; Dennis M Higgins; William T Ruyechan
Journal:  Neurobiol Dis       Date:  2006-12-20       Impact factor: 5.996

6.  Nuclear import of the varicella-zoster virus latency-associated protein ORF63 in primary neurons requires expression of the lytic protein ORF61 and occurs in a proteasome-dependent manner.

Authors:  Matthew S Walters; Christos A Kyratsous; Shilin Wan; Saul Silverstein
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Authors:  Mohamed I Khalil; Marvin Sommer; Ann Arvin; John Hay; William T Ruyechan
Journal:  Virology       Date:  2013-03-21       Impact factor: 3.616

8.  Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency.

Authors:  Susan E Hoover; Randall J Cohrs; Zoila G Rangel; Donald H Gilden; Peter Munson; Jeffrey I Cohen
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Construction of recombinant mouse IgG1 antibody directed against varicella zoster virus immediate early protein 63.

Authors:  Niklaus H Mueller; Laurie L Graf; Andrew J Shearer; Gregory P Owens; Donald H Gilden; Randall J Cohrs
Journal:  Hybridoma (Larchmt)       Date:  2008-02

10.  The phosphorylation profile of protein kinase A substrates is modulated during Varicella-zoster virus infection.

Authors:  Nathalie Desloges; Markus Rahaus; Manfred H Wolff
Journal:  Med Microbiol Immunol       Date:  2007-12-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.